|
Powered by Cell Signaling Technology |
|
Powered by Cell Signaling Technology |
| Site Information |
|---|
| AMBIGUOUS SITES: HSP105 (human): , HSPA4L (human): |
| GKMIMQDkLEKERND SwissProt Entrez-Gene |
| Blast this site against: NCBI SwissProt PDB |
| Site Group ID: 21176534 |
| In vivo Characterization | |
|---|---|
| Methods used to characterize site in vivo: | |
| Relevant cell line - cell type - tissue: | |
| Upstream Regulation | |
|---|---|
| Treatments: | |
| References | |
|---|---|
|
Halim VA, et al. (2018) Doxorubicin-induced DNA Damage Causes Extensive Ubiquitination of Ribosomal Proteins Associated with a Decrease in Protein Translation. Mol Cell Proteomics
29438997 Curated Info |
|
|
Udeshi ND, et al. (2013) Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 12, 825-31
23266961 Curated Info |
|
|
Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40
21906983 Curated Info |
